Zobrazeno 1 - 10
of 13
pro vyhledávání: '"Kenneth Yanek"'
Autor:
Marc P. Posner, Kellie J. Archer, Eric M. Gibney, Anne King, Kenneth Yanek, Maria I. Capparuccini, Martin J. Mangino, Daniel G. Maluf, Robert S. Fisher, Valeria R. Mas, Catherine I. Dumur
Publikováno v:
Transplantation. 85:626-635
Background Delayed graft function (DGF) after kidney transplantation (KTx) ranges between 2% and 50%. The mechanisms leading to DGF deserve special interest because DGF exerts negative influences on long-term outcomes. We studied gene expression prof
Autor:
Robert A. Fisher, Marc P. Posner, Kellie J. Archer, Eric M. Gibney, Kenneth Yanek, Adrian Cotterell, Daniel G. Maluf, Valeria R. Mas, Anne L. King
Publikováno v:
Molecular Medicine. 14:276-285
Loss of kidney graft function with tubular atrophy (TA) and interstitial fibrosis (IF) causes most kidney allograft losses. We aimed to identify the molecular pathways involved in IF/TA progression. Kidney biopsies from normal kidneys (n = 24), norma
Publikováno v:
Transplantation. 84:1262-1271
BACKGROUND Physiological angiogenesis occurs during liver regeneration, leading to the formation of new functional sinusoids. Pathological angiogenesis occurs in hepatocellular carcinoma (HCC). We aimed to evaluate the expression of angiogenic factor
Autor:
Robert A. Fisher, Eric M. Gibney, Daniel G. Maluf, Valeria R. Mas, Kellie J. Archer, L.A. Mas, Kenneth Yanek, Adrian Cotterell, Marc P. Posner, Anne L. King
Publikováno v:
Molecular Medicine. 13:315-324
Non-invasive monitoring may be useful after kidney transplantation (KT), particularly for predicting acute rejection (AR). It is less clear whether chronic allograft nephropathy (CAN) is also associated with changes in urine cells. To identify non-in
Autor:
Valeria R. Mas, Daniel G. Maluf, Catherine I. Dumur, Robert A. Fisher, Bridgette Williams, Kellie J. Archer, Kenneth Yanek
Publikováno v:
Transplantation. 83:973-981
Background. Liver transplantation (LT) represents a curative treatment for small hepatocellular carcinoma (HCC). Potentially curable higher-stage HCC patients are denied LT due to the lack of cancer markers that predict progression and recurrence. Me
Autor:
Valeria R. Mas, Kenneth Yanek, Catherine I. Dumur, Daniel G. Maluf, Colleen Jackson-Cook, Robert A. Fisher, Kellie J. Archer
Publikováno v:
Diagnostic Molecular Pathology. 15:90-94
Hepatocellular carcinoma (HCC) is the fifth most common cancer in the world. Liver transplantation represents the potentially curative treatment for small HCC. Recurrence after surgical resection and liver transplantation remains one of the major obs
Autor:
Kenneth Yanek, Robert A. Fisher, Daniel G. Maluf, Valeria R. Mas, Kellie J. Archer, Andrea Ferreira-Gonzalez, Anne King, Marc P. Posner
Publikováno v:
Transplantation. 80:1705-1711
BACKGROUND Hypercholesterolemia (HCHL) and hypertriglyceridemia (HTRG) have emerged as the most significant metabolic consequences of therapy with sirolimus. Lipid status can be exacerbated by a variety of factors in the posttransplant setting, inclu
Autor:
Daniel G. Maluf, Valeria R. Mas, Kenneth Yanek, Karen Bornstein, Robert A. Fisher, Kellie J. Archer
Publikováno v:
Transplantation. 87(1)
Progression from chronic hepatitis C virus (HCV) infection to cirrhosis and hepatocellular carcinoma (HCC) results in protein changes in the peripheral blood. We evaluated global protein expression in plasma samples of HCV-cirrhotic and HCV-cirrhotic
Autor:
Valeria R. Mas, Kim M. Olthoff, Chris E. Freise, Daniel G. Maluf, Kenneth Yanek, Robert A. Fisher, Rafik M. Ghobrial, Kellie J. Archer, Laura Kulik, Paula McIver, Xiangrong Kong
Publikováno v:
Molecular medicine (Cambridge, Mass.). 15(3-4)
The role of chronic hepatitis C virus (HCV) in the pathogenesis of HCV-associated hepatocellular carcinoma (HCC) remains controversial. To understand the transition from benign to malignant, we studied the gene expression patterns in liver tissues at
Autor:
Robert S. Fisher, Adrian Cotterell, Davis Massey, Marc P. Posner, Eric M. Gibney, L.A. Mas, Kenneth Yanek, Daniel G. Maluf, Valeria R. Mas, Anne King, Kellie J. Archer
Publikováno v:
Transplantation. 83(4)
BACKGROUND Chronic allograft nephropathy (CAN) is a cause of graft loss. The multistage processes that result in CAN are poorly understood. Noninvasive assays for detecting allograft dysfunction and predicting long-term outcomes are a priority in tra